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Four commercial enzyme immunoassays (EIAs) for the detection of Clostridium difficile toxin A have recently
been developed and marketed (Premier, Meridian Diagnostics, Cincinnati, Ohio; VIDAS, bioMerierux Vitek,
Inc., Hazelwood, Mo.; Tox-A-Test, TechLab, Blacksburg, Va.; and Bartels, Baxter Diagnostics, McGaw Park,
Ill.). The performances of these EIAs were compared with those of the tissue culture cytotoxicity assay and a
definition of C. difficik-associated disease based on both laboratory and clinical criteria for 329 clinical
specimens. Two EIAs (Premier and VIDAS) showed good overall agreement (96 and 95%, respectively) with
the cytotoxicity assay. However, they were less sensitive (84 and 71%, respectively) than the Bartels (94%) or
Tox-A-Test (93%) EIAs. The Bartels and Tox-A-Test assays were much less specific, resulting in poor positive
predictive values (56%) of the two assays when compared with that of the cytotoxicity assay. Tox-A-Test had
the added drawback of having a significant number of indeterminate results (6.4%). These data indicate that
the four EIAs all have specific shortcomings. When using these EIAs, testing strategies that take these
shortcomings into consideration should be developed.
Clostridium difficile is the most commonly detected agent
of infectious diarrhea in hospitalized patients (19). C. diffi-
cile-associated diarrheal disease is seen primarily in associ-
ation with prior or concurrent antimicrobial therapy (2, 14).
The organism's virulence is due to its ability to produce two
exotoxins, designated A and B. From animal model studies,
the pathophysiology produced by this organism has been
shown to be due primarily to toxin A, which displays
enterotoxic activity. Toxin B, which is cytotoxic, plays a
minor role, although it can act synergistically with toxin A
(12, 14).
Requests for the laboratory diagnosis of C. difficile-asso-
ciated disease are frequently made. The time-honored
method for organism detection, culture, is of limited value in
the diagnosis of C. difficile for two reasons. First, the
asymptomatic carriage rate of this organism may be as high
as 20% in patients receiving antibiotics (20), making inter-
pretation of positive culture data difficult. Second, organ-
isms that do not produce toxin are thought to be avirulent (2,
14). Isolates must be proven to produce toxin to be consid-
ered pathogenic.
The method frequently referred to as the "gold standard"
for the laboratory diagnosis of C. difficile-associated disease
is the tissue culture cytotoxicity assay (2). The assay has
been found to be positive for >90% of patients with C.
difficile-associated disease and it also has excellent specific-
ity (2, 14). The drawbacks of the assay are that it is
labor-intensive, has a slow turnaround time, detects primar-
ily toxin B, and, until a commercially available system
became available, was not well standardized.
Because of the importance of toxin A in the pathophysi-
ology of C. difficile-associated disease, attempts have been
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made to develop commercially a test that can be used to
detect this toxin. The first attempt was a latex agglutination
test which purported to detect toxin A. That test had two
significant drawbacks. First, it was learned that it did not
detect toxin A but a C. difficile cell-associated protein (13,
15). Second, in many but not all studies (10, 11, 17, 18), it
was found to be not nearly as sensitive (56 to 85%) as the
cytotoxicity assay.
Another approach has been to develop commercial en-
zyme immunoassays (EIAs) for the detection of toxin A.
ELAs have the potential of greatly simplifying and improving
the efficiency of the laboratory diagnosis of C. difficile-
associated disease. In the study described in this report, the
performance of four U.S. Food and Drug Administration-
approved, commercially available EIAs for the detection of
toxin A were compared on the basis of the following four
criteria: (i) performances compared with that of the cytotox-
icity assay, (ii) performances compared with a definition of
C. difficile-associated disease based on both laboratory and
clinical criteria, (iii) cost, and (iv) ease of performance.
MATERIALS AND METHODS
Specimen source and handling. A total of 329 diarrheal
fecal specimens (specimens which took the form of the
specimen cup) submitted to the Bacteriology Laboratory at
the University of North Carolina Hospitals between May
1991 and April 1992 for C. difficile toxin detection were
studied. The specimens were primarily from adult inpatients,
although a small number of specimens were from adult
outpatients and children. The specimens were held at 4°C for
between 2 and 24 h before assay. The C. difficile Tox-A-Test
EIA (TechLab, Blacksburg, Va.) required that 0.4 ml of
fecal specimen be added to 0.4 ml of specimen buffer
immediately upon receipt in the laboratory and be refriger-
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ated until testing. For each specimen, four EIAs for detec-
tion of C. difficile toxin A, a tissue culture cytotoxicity
assay, and culture for toxigenic organisms were performed
within 24 h of receipt.
EIAs. (i) Meridian Premier. The Meridian Premier assay
(Meridian Diagnostics, Cincinnati, Ohio) was performed
according to the manufacturer's instructions as described
previously (6, 9). The absorbance for each assay was deter-
mined by taking a dual-wavelength reading at 450 and 630 nm
by using a Whittaker Bioproducts (Walkersville, Md.) EIA
400 AT reader. A positive test was an optical density at 450
and 630 nm (OD4501630) reading of .0.10, an indeterminate
test was an OD450/630 reading of 20.07 but <0.10, and a
negative test was an OD450/630 reading of <0.07. Specimens
with indeterminate results were stored at -20°C and were
assayed one additional time when the next series of assays
was done.
(ii) VIDAS C. dijicile toxin A assay. For the VIDAS C.
difficile toxin A assay (BioMerieux Vitek, Inc., Hazelwood,
Mo.), specimens were prepared by adding 1 ml of sample to
1 ml of sample treatment reagent and vortexing vigorously.
This mixture was centrifuged at 12,000 x g for 5 min. Next,
300 jtl of supernatant was pipetted into each of the two
sample wells of a dual-reagent strip. Positive and negative
controls were added to their respective strips. Strips were
loaded onto the VIDAS module. Solid-phase receptacles,
which were coated with rabbit anti-C. difficile toxin A, were
placed into the machine. Test reactions occurred in the
solid-phase receptacles, which serve the same purpose as
microtiter wells in a conventional EIA. The assay was
initiated via computer commands, and all steps of the
sequential enzyme-linked fluorescent immunoassay were
performed automatically by the VIDAS module in 2.5 h.
Specimens with test values of <-300 were invalid, those
with test values from > -300 to 130 were negative, those
with test values from >130 to <235 were equivocal, and
those with test values of >235 were positive. Specimens
with invalid or equivocal results were stored at -20°C and
were assayed one additional time when the next series of
assays was done. Invalid or equivocal results were classified
as indeterminate for data analysis purposes.
(iii) Bartels C. difficile toxin A ETA. The Bartels C. difficile
toxin A EIA (Baxter Diagnostics, McGaw Park, Ill.) was
performed according to the manufacturer's instruction.
Briefly, 1 ml of sample was added to 1 ml of specimen
treatment buffer, vortexed, and centrifuged at 2,000 x g for
10 min. One hundred microliters of supernatant was pipetted
into a well coated with mouse immunoglobulin G to C.
difficile toxin A. Three negative controls and one positive
control were included in each assay. Plates were next
incubated for 90 min and washed four times with wash
solution, one drop each of rabbit immunoglobulins to C
difficile toxin A and peroxidase-labeled goat anti-rabbit
antibodies was added to each well, and the plates were
incubated at 37°C for 30 min. Each well was again washed
four times. One drop each of enzyme substrate and H202
peroxidase solution was added to each well. Plates were
covered and incubated in the dark at ambient temperature
for 15 min. Two drops of stop solution were added to each
well, and the absorbance at OD450 was determined with the
Whittaker EIA reader. The mean negative control value was
calculated by dividing the sum of the absorbances of the
three negative controls by three. The assay was negative if
the result for the specimen was less than the mean negative
control value plus 0.099. Specimens were determined to be
indeterminate when the results were between the mean
negative control value plus 0.1 to 0.149. A specimen was
positive when the OD450 reading was 0.15 plus the mean
negative value or greater. Specimens with indeterminate
results were stored at -20°C and were assayed one addi-
tional time when the next series of assays was done.
(iv) C. difficile Tox-A-Test. The procedure for performing
the Tox-A-Test EIA (TechLab) was essentially the same as
that described above for the Premier EIA, with the excep-
tion of sample preparation, which has already been dis-
cussed. At the completion of assay, the absorbance was
determined at OD450 with the Whittaker EIA reader. A
specimen with an OD450 of <0.10 was considered negative,
one with an OD450 of 0.10 to 0.199 was considered indeter-
minate, and one with an OD450 of .0.20 was considered
positive. Specimens with indeterminate results were stored
at -20°C and were repeat tested when the next series of
assays was done.
All specimens with indeterminate results by each EIA
which could not be resolved as either positive or negative on
repeat testing were reported as indeterminate. Indeterminate
results were not included in the data analysis when compar-
ing the results of the EIAs with that of either the tissue
culture cytotoxicity assay or the diagnosis of C. difficile-
associated disease.
Tissue culture cytotoxicity assay. All specimens were as-
sayed for cytotoxicity as described previously (9). Briefly,
filtered fecal extracts were tested at final dilutions of 1:8 and
1:40 for a typical cytopathic effect (CPE) on an MRC-5
fibroblast cell line. Specimens showing a typical CPE during
a 36- to 48-h assay period were then processed in a neutral-
ization assay. If a CPE was seen in the 1:40 dilution, 50 pl of
fecal extract was incubated with 200 p,l of a 1:10 dilution of
C. difficile antitoxin (provided by Tracy Wilkins, Virginia
Polytechnic Institute and State University Blacksburg) and a
1:10 dilution of fetal calf serum (FCS) as a negative control.
If a CPE was seen only in the 1:8 dilution, 50 ,ul of fecal
extract was incubated with an equal volume of the two
serum specimens. These mixtures were then assayed by
adding 50 ,ul of each to duplicate wells. Specimens were
considered to be positive for C. difficile toxin if the anti-C.
difficile toxin neutralized the CPE while a CPE was still
observed in the fecal extract-FCS mixture. By this ap-
proach, nonspecific toxicity, i.e., CPEs in both the fecal
extract-antitoxin and fecal extract-FCS mixtures, was not
observed.
Culture for toxigenic C. difficile. Fecal specimens were
cultured by three different methods. Stool specimens were
inoculated directly onto cycloserine-cefotoxin-fructose agar
(8). Swabs taken from each fecal specimen were placed in
glass tubes and incubated at 70°C in a heat block for 15 min
and were then inoculated onto brain heart infusion (BHI)-
sheep blood agar. One milliliter of stool specimen was
combined with 1 ml of absolute ethanol, and the mixture was
shaken for 30 min. Specimens were then inoculated onto
BHI-sheep blood agar. All plates were incubated at 35°C for
48 to 72 h in an anaerobic chamber. Colonies showing typical
C. difficile morphology were confirmed by Gram staining and
culture as anaerobic, gram-positive rods and were identified
by the Vitek anaerobe identification system. Isolates con-
firmed as C. difficile were inoculated into BHI broths and
incubated for 48 to 72 h. Culture supernatants were tested
for toxin activity by the cytotoxin assay described above.
Definition of C. diffldile-associated disease. Patients were
defined as having C. difficile-associated disease if they had
both antibiotic-associated diarrhea and either a positive
cytotoxicity assay for C. difficile toxin or a positive culture
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TABLE 1. Results of four EIAs for detection of C. dificile
toxin A and tissue culture cytotoxicity for C. difficile cytotoxin
on 329 clinical specimens
No. of specimens
Result"
Premier VIDAS Bartels Tox-A-Test
EIA +, cytotoxin + 27 22 30 28
EIA -,cytotoxin + 5 9 2 2
EIA +,cytotoxin - 9 7 24 22
EIA -, cytotoxin - 285 286 273 256
EIA ind, cytotoxin - 3 4 0 19
EIA ind, cytotoxin + 0 1 0 2
a EIA +, EIA positive; EIA -, EIA negative; EIA ind., EIA repeatedly
indeterminate; cytotoxin +, cytotoxin assay positive; cytotoxin -, cytotoxin
assay negative.
for cytotoxin-producing C difficile. Patients were judged to
have antibiotic-associated diarrhea if they were currently
receiving or had received antibiotics in the past 8 weeks and
had had at least six stools in the prior 48 h (16). In some
cases, the number of bowel movements were not well
documented in the patient's chart. These patients were
judged to have diarrhea if it was specifically mentioned in the
patients' progress notes or problem lists in the 48 h prior to
testing. Charts were available for review for 33 of 35 patients
who had a positive cytotoxicity assay or toxigenic culture
result.
Cost analyses. Cost analyses of the EIAs were based on
the manufacturer's list price and an assay done with five
samples and the appropriate positive and negative controls.
The cost per assay reflected only the kit costs and not those
of other consumables or the technologist's time. The cost of
the tissue culture cytotoxicity assay was based on the cost of
the Bartels tissue culture cytotoxicity kit and the cost of a
filter and syringe to process the specimen. Culture cost was
based on the list price of a cycloserine cefoxitin fructose agar
plate, one BHI plate and broth, used for 20% of the speci-
mens tested (Becton-Dickinson Microbiology Systems,
Cockeysville, Md.), one Vitek anaerobic identification card
done, used for 20% of the specimens tested, and two assay
wells in the Bartels tissue culture cytotoxicity assay kit used
for 20% of the specimens tested.
RESULTS
The performances of the four EIAs showed varying levels
of agreement with the tissue culture cytotoxicity assay
(Tables 1 and 2). The Premier (96%) and VIDAS (95%) EIAs
showed the highest correlations with the cytotoxicity assay.
However, this high level of correlation was due primarily to
the highly specific natures of these assays. The sensitivities
TABLE 2. Statistical comparison of four EIAs for detection
of C. difficile toxin A with a tissue culture cytotoxicity assay
for C. difficile cytotoxin
ETA Sensitivity Specificity Correlation pPva NPVb(%) (%) (%) (%) (%)
Premier 84 97 96 75 98
VIDAS 71 98 95 76 97
Bartels 94 92 92 56 99
Tox-A-Test 93 92 92 56 99
a PpV, positive predictive value.
b NPV, negative predictive value.
TABLE 3. Results of culture and tissue culture cytotoxicity
assay for C. difficile compared with four EIAs positive for
C. difficile toxin A
Result' No. of specimens with positive results bythe following ETA:
TCA Culture Premier VIDAS Bartels Tox-A-Test
+ Tox + C. difficile 24 20 26 24
+ Negative 3 1 4 4
- Tox + C. difficile 1 0 2 2
- Tox- C. difficile 1 0 2 1
- Negative 7 7 20 19
a TCA, tissue culture cytotoxicity assay; Tox + C. difficile, culture positive
for cytotoxin-producing C. difficile; Tox - C. difficile, culture positive for C
difficile isolates which do not produce cytotoxin.
of these two assays were substantially lower (Premier, 84%;
VIDAS, 71%) when compared with those of the Bartels and
Tox-A-Test assays (94 and 93%, respectively). The compar-
atively higher sensitivities of the Bartels and Tox-A-Test
assays were due, in part, to their lower specificities. This
resulted in comparatively poor positive predictive values
(56%) for the two assays. However, an alternative explana-
tion for these poor predictive values when compared with
that of the cytotoxicity assay was that these two EIAs were
more sensitive than the cytotoxicity reference method. To
test this hypothesis, an alternative detection method, culture
for toxigenic C. difficile organisms, was also evaluated. Four
of the 24 Bartels EIA-positive, cytotoxin-negative speci-
mens were culture positive (Table 3). Two of the four
cultures produced cytotoxin. Of these two, only one was
isolated from a patient with a clinical presentation consistent
with C. difficile-associated disease. For the 22 Tox-A-Test
EIA-positive, cytotoxin-negative specimens, only 1 speci-
men was from a patient who was judged to have C. difficile-
associated disease. These data indicated that 23 of 24 Bartels
EIA-positive, cytotoxin assay-negative and 21 of 22 Tox-A-
Test EIA-positive, cytotoxin assay-negative specimens were
likely to be false positives.
The four assays were also compared with a reference
method on the basis of a definition of C. difficile-associated
disease. The definition of C. difficile-associated disease was
based on clinical findings of antibiotic-associated diarrhea,
as determined by chart review, and the presence in feces of
either cytotoxin or a toxigenic C difficile strain. Thirty-five
specimens met the laboratory criteria of the disease defini-
tion (32 cytotoxin-positive and 3 toxigenic culture-positive
specimens). Charts were reviewed for patients from whom
33 of the 35 laboratory-positive specimens were obtained.
When C. difficile-associated disease instead of the cytotox-
icity assay was used as a reference method, a major differ-
ence in the results was that the predictive value of a positive
result dropped from 56 to 50% for both the Bartels and
Tox-A-Test assays (Table 4). This was due to the observa-
tion that three of the cytotoxin-positive specimens were
obtained from patients without antibiotic-associated diar-
rhea and, therefore, did not meet the C. difficile-associated
disease definition. Two of these three specimens were pos-
itive by the Premier, Bartels, and Tox-A-Test ELAs. The
VIDAS assay was either negative (n = 2) or indeterminate (n
= 1) for all three specimens.
An important factor when evaluating these assays was
determining the number of specimens that were indetermi-
nate, i.e., uninterpretable on initial assay, and how many
were not resolved, i.e., remained uninterpretable after re-
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TABLE 4. Statistical comparison of four EIAs for detection of
C. difficile toxin A with C. difficile-associated disease
EIA Sensitivity Specificity Correlation pPva NPVb(%) (%) (%) (%) (%)
Premier 86 97 96 73 99
VIDAS 79 98 96 76 98
Bartels 96 91 91 50 99
Tox-A-Test 93 91 91 50 99
a PpV, positive predictive value.
b NPV, negative predictive value.
peat testing. For the Premier assay, 7 specimens were
uninterpretable initially and 3 remained unresolved; for the
Bartels, Vidas, and Tox-A-Test ETAs, the values were 8 and
0, 16 and 5, and 50 and 21, respectively. One of the 5
uninterpretable specimens assayed by the VIDAS EIA and 1
of 21 uninterpretable specimens assayed by the Tox-A-Test
EIA were from patients with C. difficile-associated disease.
Another area of concern when evaluating these assays is
cost. Costs can be evaluated in two ways. One is the cost of
the assay, which is easy to determine. The other is the cost
to the patient if the test is inaccurate or has a slow turn-
around time. This cost is significantly more difficult to
determine. The costs were as follows: culture materials,
$3.76; cytotoxicity assay, $7.15; Premier EIA, $8.39; Tox-
A-Test EIA, $9.48; Bartels EIA, $10.76; and VIDAS EIA,
$14.00. These costs were based on the list prices of the assay
or culture material and a test run of five samples. On the
basis of hands-on technical time and turnaround time, the
VIDAS EIA, although the most expensive assay, was also
the most efficient assay. However, it had the added disad-
vantage of requiring its own instrument, while the other
EIAs could be read with a standard EIA reader. The Bartels
EIA was slightly more complex, requiring additional incu-
bation and wash steps compared with either the Premier or
the Tox-A-Test EIA. All four EIAs gave same-day results.
The tissue culture cytotoxicity assay required extensive
sample preparation times and a 24- to 48-h incubation period.
It also required expertise in interpreting the cytotoxic reac-
tions. Culture is the most familiar technique to microbiolo-
gists, and it is inexpensive. However, it has a slow turn-
around time, especially for positive cultures (3 to 5 days). To
be most accurate, the ability of the isolate to produce toxin
should be determined.
DISCUSSION
The performances of four EIAs for the detection of C.
difficile toxin A were assessed. The Premier and VIDAS
EIAs had the best correlation when compared with either a
cytotoxicity assay or diagnosis of C. difficile-associated
disease. This superior performance was due to the excellent
specificities of the two assays (Premier EIA, 97% versus
cytotoxicity assay; VIDAS EIA, 98% versus cytotoxicity
assay). These two assays were not as sensitive as either the
Bartels EIA (94% versus cytotoxicity assay) or the Tox-A-
Test EIA (93% versus cytotoxicity assay). The assays with
higher sensitivities were less specific (92%). These data
indicate that in order to improve the sensitivities of these
two assays, specificities were sacrificed. The observation
that 23 of 24 Bartels EIA-positive, cytotoxin assay-negative
and 21 of 22 Tox-A-Test EIA positive, cytotoxin assay-
negative specimens were probable false positives on the
basis of a C. difficile-associated disease definition further
supports that observation.
Only the Premier assay has been evaluated extensively (1,
3-7, 9). The assay's performance in the present study
(Tables 2 and 4) is in general agreement with those described
in four other reports. In those studies, the investigators
found the Premier EIA to have a sensitivity of 84 to 89%
(4-6, 9) and to be highly specific when compared with the
tissue culture cytotoxicity assay. In three other studies (1, 3,
7), the sensitivity of the assay was found to be significantly
low (69 to 72%), although the investigators also found the
assay to be highly specific. A possible explanation for these
discrepancies could be due to differences in how the refer-
ence method, which is not well standardized, was per-
formed. However, both DiPersio et al. (6) and Doern et al.
(7) used the same standardized tissue culture assay. DiPer-
sio's group found a sensitivity of 84% for the Premier assay
when it was compared with the cytotoxicity assay, while
Doern's group observed a sensitivity of 69%. Therefore, the
reason for the discrepancy between the sensitivities of the
assay in different laboratories is unclear.
The other assay for which other evaluations have been
reported is the VIDAS EIA. The VIDAS assay was the least
sensitive assay of the four examined in the present study.
The sensitivity (71% versus cytotoxicity assay) was similar
to that reported in two other studies (68 and 63%). The assay
was found to be highly specific (98% versus cytotoxicity
assay). This is in agreement with the study of Barbut et al.
(1), who found 100% specificity, but is in disagreement with
a study of Shanholtzer et al. (17), who found a specificity of
only 75%. The explanation for this difference in specificity is
unknown.
Repeat testing of the VIDAS assay was required for 16
specimens (4.8%) because of uninterpretable results. Five
(1.5%) were still uninterpretable after repeat testing. Barbut
et al. (1) found a similar uninterpretable rate (2.5%). Shan-
holtzer et al. (17), who did not do repeat testing on all their
specimens, found an indeterminate rate of 19% on initial
testing. They were able to resolve 7 of 12 specimens on
repeat testing. If their resolution rate was applied to all 36
specimens, 7.7% of the specimens would have been unre-
solved even after repeat testing. The reason for the discrep-
ancy between the data of Shanholtzer et al. (17) and the data
reported here is unknown.
There are no reports concerning the performance of either
the Bartels or the Tox-A-Test EIA. Both tests are highly
sensitive, but because they have comparatively poor speci-
ficities, the positive predictive values of these assays are
56% when compared with the cytotoxicity assay and only
50% when compared with the case definition of C difficile-
associated disease. These data indicate that an alternative
method should be used to confirm the results for at least
some specimens with positive assay results. For example, in
the Bartels ETA, the positive predictive value compared with
the cytotoxicity assay was 85% (23 of 27) for specimens with
an OD450 of >1 and 94% when the OD450 was >2. Since the
negative predictive value for these assays exceeded 99%,
negative results, which make up approximately 90% of the
specimens tested, would not need to be confirmed.
Indeterminate results were a significant problem with the
Tox-A-Test assay, requiring repeat testing of 50 specimens
(15%). Approximately 6% of specimens were uninterpret-
able even after repeat testing. The need to retest a significant
number of specimens and the large numbers of indeterminate
results are important drawbacks to the Tox-A-Test assay.
Cost and ease of use were two other factors considered in
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the present study. The direct costs are greater for the EIAs
than for culture or the cytotoxicity assay. However, the
EIAs all have a significant advantage over culture or the
cytotoxicity assay. Even with the possible need to confirm
positive results in the Bartels and Tox-A-Test assays, an
answer is available for 80 to 90% of the specimens on the
same day of testing. Culture, if isolate toxigenicity is deter-
mined, may take as long as 5 days, while cytotoxicity takes
24 to 48 h. The tests are also less labor intensive than culture
or the cytotoxicity assay. Those two factors indicate that the
overall expense for the EIAs will be less than that for culture
or the cytotoxicity assay. A possible exception may be the
Tox-A-Test EIA. This is due to the potentially large number
of specimens for which repeat testing may be required.
Microbiologists are faced with distinct options when
choosing which C. difficile toxin A ETA they might adopt in
their laboratories. The Premier EIA had the best perfor-
mance of the four assays studied. However, the sensitivity
of this test is approximately 85%. That means a number of
positive specimens will be missed by this assay. If physi-
cians have a high index of suspicion that a patient has C.
difficile-associated disease, repeat specimens from that pa-
tient should be assayed if the initial specimen is negative. A
similar approach should be adopted for the VIDAS EIA
system, which is even less sensitive. An additional factor
when considering the VIDAS EIA is expense. The cost per
VIDAS EIA was the highest of the four EIAs, and it requires
an expensive, specialized piece of equipment. This is offset
to some degree by the fact that the assay requires the least
amount of technologist time and is technically simple. Be-
cause of the low sensitivity of this assay in three separate
evaluations (1, 17; this study), the utility of the VIDAS assay
for diagnostic testing must be questioned. Both the Bartels
and Tox-A-Test EIAs were highly sensitive, but approxi-
mately 45% of the positive specimens were false positives
when compared with results of the cytotoxicity assay. Lab-
oratories considering using these tests should have methods
which could be used to confirm positive specimens, espe-
cially those with OD450 values of <1.
Tissue culture cytotoxicity continues to be the most
accurate method for detecting C. difficile toxins in stool
specimens. Each of the four ELAs for the detection of C.
difficile toxin A has specific shortcomings. Laboratories that
adopt any of these assays should be aware of these short-
comings. When clinical situations arise in which confirma-
tion of EIA results is needed, alternate methods should be
available.
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